Taysha Gene Therapies (TSHA) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap families, a change that can influence trading flows as passive funds rebalance.

Despite the index removals, Taysha Gene Therapies’ recent share price performance has been strong, with a 30 day share price return of 22.57% and a 90 day share price return of 46.33%, while the 1 year total shareholder return sits at a very large gain.

If this kind of move has you looking beyond a single biotech, it could be a good moment to scan the wider healthcare opportunity set using our 40 healthcare AI stocks

Taysha Gene Therapies has delivered very strong recent returns despite being dropped from multiple Russell indexes. The key question now is whether the current share price still reflects an attractive entry or whether enthusiasm has already been fully priced in.

Most Popular Narrative: 48.9% Undervalued

At a last close of $6.57 versus a narrative fair value of $12.85, Taysha Gene Therapies is framed as significantly undervalued in the most followed model.

Progress in the clinical development of TSHA-102, particularly moving towards the pivotal phase of the REVEAL trials with promising safety and efficacy data, could enhance investor confidence and potentially lead to future revenue growth once regulatory approval is achieved. Ongoing constructive discussions with the FDA about the regulatory pathway for TSHA-102, including potential expedited approval mechanisms like the RMAT designation, may accelerate product approval and market entry, thereby impacting future earnings positively.

Curious what assumptions sit behind that near doubling of fair value? The projected ramp in revenue, shifts in profitability, and the punchy future earnings multiple all feed into this narrative.

Result: Fair Value of $12.85 (UNDERVALUED)

However, Taysha Gene Therapies still faces meaningful risks, including the possibility that TSHA-102 trial results or FDA feedback fall short of the assumptions embedded in this upbeat narrative.

Next Steps

With Taysha Gene Therapies framed as both promising and risky, it makes sense to move quickly, review the key data yourself, and weigh up the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Taysha Gene Therapies?

If Taysha Gene Therapies has sharpened your focus, now is the time to widen your watchlist and uncover other stocks that could suit your approach.

• Spot potential turnaround stories early by scanning 20 elite penny stocks with strong financials before the crowd catches on.
• Zero in on quality companies that may trade below their estimated worth using the 44 high quality undervalued stocks.
• Build a steadier core to your portfolio by checking stocks in the 73 resilient stocks with low risk scores that come with resilience front and center.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.